StemExpress

📍 Folsom, United States🗓 Founded 2010👥 75 employees💰 Last funded Jan 2019
StemExpress was founded in 2010 to accelerate the cure and prevention of significant medical conditions at life-changing speed. StemExpress supports cell and gene therapies, commercialization of disease specific treatments, medical research, clinical trials, precision/regenerative medicine, among other researchers and clinicians around the world who are developing and implementing revolutionary treatments and cures. StemExpress is currently the nation's leading biospecimen provider of human primary cells, stem cells, human bone marrow, cord blood, peripheral blood, maternal blood, and disease-state products for academic, biotechnological, diagnostic, pharmaceutical and contract research organizations. StemExpress is registered with the U.S. Food and Drug Administration (FDA) and has seven (7) independently owned and operated brick-and mortar cellular clinics across the United States to collect blood, cells and tissue from patients and donors. These clinics include state-of-the-art cell manufacturing laboratories for clinical and research purposes, and CLIA certified/high-complexity diagnostics. #celltherapy #genetherapy #primarycells #immunotherapy #immunology #cancerresearch #biotechnology #biospecimens #cancerresearch #biomedicalresearch #stemcellresearch #covidtesting
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2010
Founded
Investor geography1 country
United States
1
Frequently asked questions
Who invested in StemExpress?
StemExpress has 1 investors on record on gritt.io and 1 late-stage investors.
When did StemExpress last raise funding?
The most recent investment in StemExpress recorded on gritt.io was in January 2019.
When was StemExpress founded?
StemExpress was founded in 2010.
What industry is StemExpress in?
StemExpress operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is StemExpress based?
StemExpress is headquartered in Folsom, United States.